DXS International plc (AQSE: DXSP), the UK healthcare technology provider, has announced that all six resolutions put to shareholders at its Annual General Meeting held on 19 November 2026 were duly passed. The AGM, which took place at 11.30am, saw voting conducted entirely on a poll. Five of the six resolutions attracted unanimous or near-unanimous support, signalling broad shareholder confidence in the company's current direction. During the meeting, Chief Operating Officer and Director Steven Bauer delivered a progress update on DXS's operations, with a presentation made available on the company's website.

Key Points

  • DXS International plc (AQSE: DXSP) is a UK healthcare technology provider delivering clinical decision support to NHS clinicians
  • All six resolutions at the 19 November 2026 AGM were passed on a poll with strong shareholder backing
  • Resolution 5 received 96.83% votes in favour, the lowest approval rate; Resolutions 1 and 2 each received 100.00% support
  • Investors may be watching for further operational updates following COO Steven Bauer's AGM progress presentation

Six Resolutions Passed at DXS International's 2026 Annual General Meeting

All six resolutions presented at DXS International's AGM on 19 November 2026 were carried by shareholders voting on a poll. Resolutions 1 and 2 each secured 100.00% of votes cast in favour, with no votes against and no votes withheld. Resolution 3 also achieved 100.00% approval with 2,890 votes withheld, while Resolution 4 passed with 99.98% support and 5,000 votes against. Resolution 6 received 99.95% approval, again with 5,000 votes against. The company notes that votes withheld are not counted in law as votes for or against any resolution.

Resolution 5 Draws Most Dissent With 3.14% Votes Against

The closest result among the six resolutions was Resolution 5, which passed with 26,448,038 votes in favour, representing 96.83% of votes cast. A total of 856,675 votes were recorded against, equating to 3.14% of the poll, with a further 7,890 votes withheld. While the resolution was comfortably carried, the level of dissent was notably higher than on the other five items. The announcement does not specify which particular matter Resolution 5 addressed, so investors seeking further detail may wish to consult the full AGM documentation available through the company.

COO Steven Bauer Delivers Operational Progress Update to Shareholders

Alongside the formal voting business, DXS International's COO and Director Steven Bauer provided shareholders with an update on the company's operational progress during the AGM. The presentation has been made available for download from DXS's corporate documents page at dxs-systems.co.uk. DXS International provides up-to-date treatment guidelines and clinical recommendations from NHS sources, including Clinical Commissioning Groups, directly to doctors, nurses, and pharmacists during patient consultations. The company positions this clinical decision support as contributing to improved healthcare outcomes and NHS efficiency savings.